Expanded Access Program for Aztreonamn Lysine for Inhalation in Patients with Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection who have Limited Treatment Options and are at Risk for Disease Progression
|Effective start/end date||1/15/08 → 12/31/10|
- Gilead Sciences, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.